These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18690920)

  • 1. Host pharmacogenetics in the treatment of HIV and cancer.
    Winston A; Hatzimichael E; Marvin V; Stebbing J; Bower M
    Curr Drug Saf; 2006 Jan; 1(1):107-16. PubMed ID: 18690920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacogenomics of antiretroviral and cytotoxic treatments.
    Stebbing J; Bower M
    Lancet Oncol; 2006 Jan; 7(1):61-8. PubMed ID: 16389185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host determinants of antiretroviral drug activity.
    Boffito M; Winston A; Owen A
    Curr Opin Infect Dis; 2005 Dec; 18(6):543-9. PubMed ID: 16258330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of anti-HIV drugs.
    Telenti A; Zanger UM
    Annu Rev Pharmacol Toxicol; 2008; 48():227-56. PubMed ID: 17883329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics in HIV therapy.
    Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nacher I; Rendón A; Soriano V
    AIDS Rev; 2005; 7(2):103-12. PubMed ID: 16092504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV pharmacogenetics in clinical practice: recent achievements and future challenges.
    Tozzi V; Libertone R; Liuzzi G
    Curr HIV Res; 2008 Nov; 6(6):544-54. PubMed ID: 18991620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting c-Myb expression in human disease.
    Ramsay RG; Barton AL; Gonda TJ
    Expert Opin Ther Targets; 2003 Apr; 7(2):235-48. PubMed ID: 12667100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical implications of antiretroviral pharmacogenomics.
    Fox J; Boffito M; Winston A
    Pharmacogenomics; 2006 Jun; 7(4):587-96. PubMed ID: 16753006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.
    Martin AM; Nolan D; Gaudieri S; Phillips E; Mallal S
    Pharmacogenomics; 2004 Sep; 5(6):643-55. PubMed ID: 15335286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
    Yan L; Beckman RA
    Biotechniques; 2005 Oct; 39(4):565-8. PubMed ID: 16235569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.
    Arab-Alameddine M; Décosterd LA; Buclin T; Telenti A; Csajka C
    Expert Opin Drug Metab Toxicol; 2011; 7(5):609-22. PubMed ID: 21500966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV-infected patients.
    Veloso S; Peraire J; Viladés C; López-Dupla M; Escoté X; Olona M; Garcia-Pardo G; Gómez-Bertomeu F; Soriano A; Sirvent JJ; Vidal F
    Curr Pharm Des; 2010 Oct; 16(30):3379-89. PubMed ID: 20687887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacogenetics of anticancer drugs].
    de Chaisemartin L; Loriot MA
    Pathol Biol (Paris); 2005 Mar; 53(2):116-24. PubMed ID: 15708657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of adverse effects due to antiretroviral drugs.
    Vidal F; Gutiérrez F; Gutiérrez M; Olona M; Sánchez V; Mateo G; Peraire J; Viladés C; Veloso S; López-Dupla M; Domingo P
    AIDS Rev; 2010; 12(1):15-30. PubMed ID: 20216907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenetics in oncology].
    Morán González D; Jiménez Cabrera S; Domínguez-Gil Hurlé A
    Med Clin (Barc); 2008 Jul; 131(5):184-95. PubMed ID: 18674490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic considerations in the treatment of HIV.
    Mattevi VS; Tagliari CF
    Pharmacogenomics; 2017 Jan; 18(1):85-98. PubMed ID: 27976978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic pharmacogenomics in cancer.
    Ikediobi ON
    Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacogenetics. Tailored therapy in medicine -- opportunities and challenges].
    Scharplatz M; Puhan M; Steurer J; Bachmann LM
    Praxis (Bern 1994); 2004 Mar; 93(10):359-65. PubMed ID: 15052854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic determinants of anti-cancer drug activity and toxicity.
    Danesi R; De Braud F; Fogli S; Di Paolo A; Del Tacca M
    Trends Pharmacol Sci; 2001 Aug; 22(8):420-6. PubMed ID: 11479005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.